Monitor Pfizer's upcoming quarterly earnings for any changes in financial strategy or capital allocation under the permanent CFO. No immediate trading catalyst from this appointment.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $30.79entry
- T+1 · 12d ago −2.96%α +1.45% · $29.88
- T+5 · 6d ago −4.35%α −3.44% · $29.45
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pfizer announced the permanent appointment of Cecile Guegan as CFO and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 2026. The filing includes her compensation package: $1.3M base salary and $1.3M target cash incentive. This is a routine succession event with no material financial impact.
Key Facts
- Cecile Guegan elected CFO and Executive Vice President effective November 1, 2026
- She had served as interim CFO since August 16, 2026
- Annual base salary of $1,300,000
- Annual target cash incentive opportunity of $1,300,000 (100% of base salary)
- Guegan has over 25 years of pharmaceutical finance experience, joined Pfizer via 2009 Wyeth acquisition
Financial Impact
Compensation package of $2.6M annual total (base + target cash incentive) for a $170.7B market cap company; no material financial impact
Risk Factors
- No material risks identified; this is a routine executive appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000132 |
| Document: pfizerappointscecileguegan.htm | 0000078003-26-000132 |
| Document: 0000078003-26-000132-index-headers.html | 0000078003-26-000132 |
| Document: 0000078003-26-000132-index.html | 0000078003-26-000132 |
| Document: 0000078003-26-000132.txt | 0000078003-26-000132 |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Viewing Entry $30.79 Now $28.89 −6.17% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.89 −3.70% settles Feb 1
- Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers